NervGen Pharma is preparing to begin patient screening in September 2026 for RESTORE, a Phase 3 registrational trial that will test whether NVG-291 can improve fine-motor hand function in adults living with chronic tetraplegia after traumatic spinal cord injury. The company expects the first participant to be dosed shortly after screening begins and plans to activate additional neurorehabilitation sites across the United States and Canada on a rolling basis. RESTORE will enroll approximately 150 adults and is expected to complete enrollment during the second half of 2027, with topline results targeted for the first half of 2028.
The study follows earlier alignment between NervGen Pharma and the United States Food and Drug Administration on the principal elements of the registrational design, including the patient population, treatment duration and primary endpoint. That regulatory alignment gives NervGen Pharma a defined late-stage strategy, but it does not mean NVG-291 is likely to be approved. The Phase 3 trial must reproduce functional improvements previously observed in a much smaller Phase 1b/2a population while generating a sufficiently convincing benefit-risk profile for a future marketing application.
RESTORE will focus on hand function as the primary measure of neurological recovery
RESTORE is a randomized, double-blind and placebo-controlled study involving adults between 18 and 75 years old with chronic cervical spinal cord injury at or above the C7 neurological level. Participants must have American Spinal Injury Association Impairment Scale Grade C or D injuries and be between one and 10 years post-injury. Patients will receive once-daily subcutaneous NVG-291 or placebo for 12 weeks, followed by four weeks of observation and an optional 12-week open-label extension.
The primary endpoint will measure change from baseline at week 12 using the GRASSP Quantitative Prehension assessment, a validated test designed to quantify fine-motor hand function. Secondary measures will examine patient and clinician impressions of improvement, independence in daily activities and lower-extremity spasticity, while blinded qualitative interviews will explore whether any measured neurological gains translate into changes that participants notice in everyday life.
Selecting hand function is particularly relevant in chronic tetraplegia because even relatively modest improvements in grasping and manipulating objects can affect independence. The trial is therefore attempting to measure functional restoration rather than relying only on physiological or neurological biomarkers.
The challenge is that people entering RESTORE will already be at least one year beyond their injury, a period when spontaneous neurological recovery is generally much less pronounced than during the early months after trauma. That feature could make a treatment-related improvement easier to distinguish from natural recovery, although chronic injury also represents an exceptionally difficult biological setting in which to restore damaged neural pathways.
CONNECT SCI data provide the rationale for Phase 3 but come from very small patient groups
RESTORE is based largely on findings from the randomized Phase 1b/2a CONNECT SCI study. In the chronic tetraplegia cohort, patients receiving NVG-291 improved by an average 3.7 points on GRASSP Quantitative Prehension at week 12 compared with 0.4 points for placebo, creating a 3.3-point treatment difference. NervGen Pharma noted that the difference exceeded the approximately two-point threshold it considers minimally important on the assessment.
Improvement continued after dosing stopped. At week 16, NVG-291-treated participants showed an average 4.4-point gain compared with 1.2 points for placebo, suggesting that some functional improvement persisted during the four-week period after treatment ended. Six of eight NVG-291-treated participants also rated themselves as much or very much improved compared with three of nine patients receiving placebo.
These findings are encouraging but statistically fragile because the groups were extremely small. With only eight active-treatment participants contributing to the reported patient-global-improvement analysis, the response of one individual can materially change the percentage. RESTORE must therefore show that the hand-function signal remains visible when the population expands from fewer than 20 relevant patients to approximately 150.
NervGen Pharma has also reported qualitative findings suggesting improvements beyond hand function. In blinded follow-up interviews conducted as long as 364 days after the Phase 1b/2a study, six of nine NVG-291-treated participants reported improved bladder control and five reported reduced muscle spasticity. These observations are exploratory and are not sufficient to establish efficacy in those domains, but they contributed to the broader rationale for including measures of independence and spasticity in the Phase 3 study.
Safety during the earlier study appeared manageable, with NervGen Pharma reporting no treatment-related serious adverse events or treatment discontinuations during 12 weeks of daily subcutaneous administration. A 150-person Phase 3 trial will provide a substantially larger safety database and should offer a better assessment of adverse events that may not emerge in small early-stage cohorts.
NVG-291 is designed to remove biological barriers that prevent nerve repair after injury
NVG-291 is a neuroreparative peptide designed to target the CSPG-PTPσ signaling pathway. Following spinal cord injury, chondroitin sulfate proteoglycans accumulate around damaged tissue and contribute to an environment that inhibits axonal regeneration, nervous-system plasticity and repair. NervGen Pharma is developing NVG-291 to interfere with that inhibitory signaling and create conditions more favorable for neural recovery.
That concept differs from treatments aimed primarily at rehabilitation, muscle control, pain or other complications following spinal cord injury. NervGen Pharma is attempting to pharmacologically influence the underlying repair environment after the injury has become chronic.
The Phase 3 study will provide the first sufficiently large test of whether that neuroreparative mechanism produces consistent functional benefit. Improvements in a handful of patients can support a biological hypothesis, but successful late-stage development requires the effect to remain reproducible across different centers, rehabilitation histories and injury characteristics.
NervGen Pharma has already selected up to 60 specialized sites in the United States and Canada, prioritizing neurorehabilitation hospitals and clinics experienced in managing spinal cord injury. A geographically broad network should support recruitment, although finding approximately 150 patients who satisfy the neurological, functional and post-injury criteria could still affect the planned 2027 enrollment timeline.
$60 million financing gives NervGen funding through its anticipated Phase 3 readout
NervGen Pharma completed a $60 million underwritten public offering during the second quarter, raising its cash and cash-equivalent position to C$86.8 million, or approximately US$61.1 million, at June 30. The company said those resources should fund operations through the anticipated RESTORE topline readout in the first half of 2028.
The financing significantly changes the near-term risk around the program because NervGen Pharma can begin the Phase 3 study without an immediate requirement to raise additional equity merely to reach the planned efficacy result. Research and development spending increased to C$7.9 million during the second quarter from C$2.7 million a year earlier, reflecting RESTORE start-up expenses, clinical manufacturing and toxicology work.
The company also established a new at-the-market equity facility of up to US$50 million in July, although no shares had been sold through the program as of the August 13 update. The additional facility provides financing flexibility but also represents a potential source of future dilution if NervGen Pharma chooses to use it.
NervGen Pharma shares were trading around $1.75 on August 13, down about 0.6% from the previous close after moving between $1.71 and $1.80 during the session. The subdued reaction suggests investors regard the September screening timeline as an execution update rather than a new clinical catalyst, with the Phase 3 outcome remaining the far more important determinant of NVG-291’s value. That interpretation is an inference from the trading pattern rather than a confirmed explanation from investors.
RESTORE therefore represents a major escalation in the evidence required from NVG-291. NervGen Pharma has FDA alignment on the study structure, specialized clinical sites, a defined functional endpoint and enough capital to reach the planned readout. The central uncertainty is whether the sizeable treatment difference observed in a very small Phase 1b/2a cohort can be reproduced across approximately 150 people with chronic tetraplegia. If it can, NVG-291 could move substantially closer to establishing a pharmacological approach aimed at restoring neurological function long after spinal cord injury rather than simply managing its consequences.
